Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Extension, Phase 2b Study to Evaluate the Longer Term Efficacy and Safety of LIB003 in Patients on Stable Lipid Lowering Therapy Requiring Additional LDL-C Reduction

NCT03847974 is registered in ClinicalTrials.gov with LIB Therapeutics LLC as lead sponsor.

NCT NCT03847974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03847974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Extension, Phase 2b Study to Evaluate the Longer Term Efficacy and Safety of LIB003 in Patients on Stable Lipid Lowering Therapy Requiring Additional LDL-C Reduction
Lead sponsor
LIB Therapeutics LLC
Phase
Phase 2
Overall status
Completed
Start date
February 14, 2019
Completion date
August 31, 2020
Enrollment
32 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hypercholesterolemia